We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Biohaven Ltd. (BHVN - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Biohaven Ltd. is one of 1183 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Biohaven Ltd. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BHVN's full-year earnings has moved 39.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, BHVN has moved about 5.6% on a year-to-date basis. At the same time, Medical stocks have lost an average of 14.7%. This means that Biohaven Ltd. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Clover Health Investments, Corp. (CLOV - Free Report) . The stock is up 7.6% year-to-date.
For Clover Health Investments, Corp. the consensus EPS estimate for the current year has increased 21.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Biohaven Ltd. belongs to the Medical - Biomedical and Genetics industry, a group that includes 560 individual stocks and currently sits at #67 in the Zacks Industry Rank. This group has lost an average of 20.1% so far this year, so BHVN is performing better in this area.
On the other hand, Clover Health Investments, Corp. belongs to the Medical Info Systems industry. This 49-stock industry is currently ranked #102. The industry has moved -47% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Biohaven Ltd. and Clover Health Investments, Corp. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Biohaven Ltd. (BHVN - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Biohaven Ltd. is one of 1183 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Biohaven Ltd. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BHVN's full-year earnings has moved 39.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, BHVN has moved about 5.6% on a year-to-date basis. At the same time, Medical stocks have lost an average of 14.7%. This means that Biohaven Ltd. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Clover Health Investments, Corp. (CLOV - Free Report) . The stock is up 7.6% year-to-date.
For Clover Health Investments, Corp. the consensus EPS estimate for the current year has increased 21.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Biohaven Ltd. belongs to the Medical - Biomedical and Genetics industry, a group that includes 560 individual stocks and currently sits at #67 in the Zacks Industry Rank. This group has lost an average of 20.1% so far this year, so BHVN is performing better in this area.
On the other hand, Clover Health Investments, Corp. belongs to the Medical Info Systems industry. This 49-stock industry is currently ranked #102. The industry has moved -47% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Biohaven Ltd. and Clover Health Investments, Corp. as they could maintain their solid performance.